Most Read

Both companies have decided to advance their BNT162b2 vaccine candidate into the phase 2/3 study at a 30µg dose level in a two-dose regimen after an extensive assessment

Currently, DS-1062 is being developed for the treatment of non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). The TROP2 directed DXd antibody drug conjugate (ADC) is

Tecartus, earlier known as KTE-X19, is claimed to be the first and only approved chimeric antigen receptor (CAR) T cell therapy to treat relapsed or refractory MCL. Tecartus,

NIAID is part of the National Institutes of Health, which is an agency of the US Department of Health and Human Services. The trial will target patients who

Gilead is also provided with an exclusive option to purchase the remaining stake in Tizona for up to an additional $1.2bn. The deal is also comprised of an

The companies have signed a collaboration agreement for the research, development, manufacturing and commercialisation of up to five messenger RNA (mRNA)-based vaccines and monoclonal antibodies (mAbs) to eliminate

AZD1222 was co-invented by Oxford University and its spin-out company Vaccitech. The recombinant adenovirus vaccine, which was licensed by AstraZeneca in May 2020, was tolerated by the participants

The in-human study follows positive pre-clinical results for the treatment candidate, as well as successive approval of the investigational new drug application by the Korean Ministry of Food

Novartis has said that it will provide medicines to governments, NGOs and other institutional customers in up to 79 eligible nations until a vaccine or curative treatment is